The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Mazurek, Michal ^a   Kowalczyk, Jacek ^a   Lenarczyk, Radoslaw ^a   Zielinska, Teresa ^a   Sedkowska, Agnieszka ^a   Pruszkowska Skrzep, Patrycja ^a   Swiatkowski, Andrzej ^a   Sredniawa, Beata ^a   Kowalski, Oskar ^a   Polonski, Lech ^a   Strojek, Krzysztof ^a   Kalarus, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute myocardial infarction; Diabetes mellitus; Glucose abnormalities; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DISEASE REGISTRY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INVASIVE PROCEDURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PROGNOSIS; PROSPECTIVE STUDY; THORAX PAIN; WORLD HEALTH ORGANIZATION;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE METABOLISM DISORDERS; GLUCOSE TOLERANCE TEST; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POLAND; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84862768434     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-78     Document Type: Article

References (33)

1. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025. Prevelance, numerical estimates and projections. Diabetes Care 1998, 21(9):1414-1431. 10.2337/diacare.21.9.1414, 9727886.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053. 10.2337/diacare.27.5.1047, 15111519.
3. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults: WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993, 16(1):157-177. 10.2337/diacare.16.1.157, 8123057.
4. Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, Mittleman MA. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001, 24(8):1422-1427. 10.2337/diacare.24.8.1422, 11473080.
5. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339(4):229-234. 10.1056/NEJM199807233390404, 9673301.
6. Mozaffarian D, Marfisi R, Levantesi G, Silletta MG, Tavazzi L, Tognoni G, Valagussa F, Marchioli R. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007, 370(9588):667-675. 10.1016/S0140-6736(07)61343-9, 17720018.
7. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, Tenerz A, Ohrvik J, Rydén L. Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004, 256(4):288-297. 10.1111/j.1365-2796.2004.01371.x, 15367171.
8. World Health Organization Report of the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus 1999, World Health Organization, Geneva, World Health Organization.
9. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J, . CIN Consensus Working Panel Epidemiology and Prognostic Implications of Contrast-Induced Nephropathy. Am J Cardiol 2006, 98(6A):5K-13K. CIN Consensus Working Panel.
10. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. A randomised trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on one year mortality. J Am Coll Cardiol 1995, 26(1):57-65. 10.1016/0735-1097(95)00126-K, 7797776.
11. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359(9324):2140-2144. 10.1016/S0140-6736(02)09089-X, 12090978.
12. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Ohrvik J, . Euro Heart Survey Investigators The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004, 25(21):1880-1890. 10.1016/j.ehj.2004.07.027, 15522466, Euro Heart Survey Investigators.
13. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Öhrvik J, Rydén L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004, 25(22):1990-1997. 10.1016/j.ehj.2004.09.021, 15541834.
14. Lenzen M, Ryden L, Öhrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W, Simoons ML, . Euro Heart Survey Investigators Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006, 27(24):2969-2974. 10.1093/eurheartj/ehl363, 17090612, Euro Heart Survey Investigators.
15. Biteker M, Dayan A, Can MM, İlhan E, Biteker FS, Tekkeşin A, Duman D. Impaired fasting glucose is associated with increased perioperative cardiovascular event rates in patients undergoing major non-cardiothoracic surgery. Cardiovasc Diabetol 2011, 10:63. 10.1186/1475-2840-10-63, 3143921, 21756307.
16. Sanjuán R, Núñez J, Blasco ML, Miñana G, Martínez-Maicas H, Carbonell N, Palau P, Bodí V, Sanchis J. Prognostic implications of stress hyperglycemia in acute ST elevation myocardial infarction. Prospective observational study. Rev Esp Cardiol 2011, 3:201-207.
17. Timmer JR, Hoekstra M, Nijsten MW, van der Horst IC, Ottervanger JP, Slingerland RJ, Dambrink JH, Bilo HJ, Zijlstra F, van 't Hof AW. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation 2011, 124(6):704-711. 10.1161/CIRCULATIONAHA.110.985911, 21768543.
18. Chan CY, Li R, Chan JY, Zhang Q, Chan CP, Dong M, Yan BP, Lam YY, Yu CM. The value of admission HbA(1c) level in diabetic patients with acute coronary syndrome. Clin Cardiol 2011, 34(8):507-512. 10.1002/clc.20915, 21717470.
19. Donahoe SM, Stewarrt GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndrome. JAMA 2007, 298(7):765-775. 10.1001/jama.298.7.765, 17699010.
20. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001, 161(14):1717-1723. 10.1001/archinte.161.14.1717, 11485504.
21. Kowalczyk J, Lenarczyk R, Strojek K, Zielinska T, Gumprecht J, Sedkowska A, Kukulski T, Swierad M, Kowalski O, Sredniawa B, Polonski L, Zembala M, Kalarus Z. Prognosis in diabetic patients with acute myocardial infarction treated invasively is related to renal function. Med Sci Monit 2010, 16(2):67-74.
22. Kim CS, Choi JS, Park JW, Bae EH, Ma SK, Jeong MH, Kim YJ, Cho MC, Kim CJ, Kim SW. Korea Acute Myocardial Infarction Registry Investigators: Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction. Cardiovasc Diabetol 2011, 31:95.
23. Høfsten DE, Løgstrup BB, Møller JE, Pellikka PA, Egstrup K. Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis. JACC Cardiovasc Imaging 2009, 5:592-599.
24. Flores-Le Roux JA, Comin J, Pedro-Botet J, Benaiges D, Puig-de Dou J, Chillarón JJ, Goday A, Bruguera J, Cano-Perez JF. Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. Cardiovasc Diabetol 2011, 10:39. 10.1186/1475-2840-10-39, 3125195, 21569580.
25. Zeymer U, Schwarzmaier-D'assie A, Petzinna D, Chiasson JL, . STOP-NIDDM Trial Research Group Effect of acarbose treatment on the risk of silent myocardial infarction in patients with impaired glucose tolerance. Results of the randomized STOP-NIDDM trial ECG substudy. Eur J Cardiovasc Prev Rehabil 2004, 11(5):412-415. STOP-NIDDM Trial Research Group.
26. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, . STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290(4):2072-2077. STOP-NIDDM Trial Research Group.
27. Zeymer U. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. Int J Cardiol 2006, 107(1):11-20. 10.1016/j.ijcard.2005.02.033, 16337493.
28. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001, 344(18):1343-1350.
29. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002, 346(6):393-403.
30. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M. Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005, 28(4):888-894. 1307521, 15793191.
31. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR, . NAVIGATOR Study Group Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. Am Heart J 2008, 156(4):623-632. 10.1016/j.ahj.2008.05.017, 18946890, NAVIGATOR Study Group.
32. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, . NAVIGATOR Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362(16):1463-1476. NAVIGATOR Study Group.
33. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, . NAVIGATOR Study Group Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362(16):1477-1490. NAVIGATOR Study Group.